Development of alendronate-loaded 3D-printed PCL/LDH scaffolds for controlled drug delivery in bone tissue engineering.
- 1Department of Biomedical Engineering, Amirkabir University of Technology (Tehran Polytechnic) Iran.
- 2Department of Polymer and Color Engineering, Amirkabir University of Technology (Tehran Polytechnic) Iran [email protected].
Abstract
Bone tissue engineering has made significant advances in recent years; however, the development of scaffolds that not only support tissue regeneration but also effectively deliver therapeutic agents remains a major challenge. The present study investigates the fabrication and evaluation of 3D-printed polycaprolactone (PCL)/layered double hydroxide (LDH) hybrid scaffolds incorporating alendronate (ALN) for bone tissue engineering applications. First, LDH particles were synthesized via a co-precipitation method and loaded with ALN. Subsequently, scaffolds with varying PCL-to-LDH ratios (2 : 1, 3 : 1, 4 : 1, and 5 : 1) were fabricated and characterized. Field emission scanning electron microscopy (FE-SEM) revealed the characteristic hexagonal morphology of the LDH particles, while X-ray diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR) analyses confirmed the successful intercalation of ALN into the LDH structure. Among the different formulations, the scaffold with a PCL-to-LDH ratio of 2 : 1 exhibited the best overall performance. The incorporation of LDH into this scaffold improved hydrophilicity, reducing the water contact angle from ∼90° to 60°, increasing the ultimate tensile strength from ∼30 to 90 MPa, enhancing the elastic modulus from ∼350 to 750 MPa, and reducing the elongation at break from ∼170% to 50%. Furthermore, ALN was uniformly dispersed within the polymer matrix, resulting in a highly similar biphasic drug release profile consisting of a slight initial burst release during the first 7 days, followed by a sustained release phase extending up to 28 days. Biological evaluations, including MTT assays, cell adhesion studies, and alkaline phosphatase (ALP) activity measurements, further demonstrated that this scaffold promoted superior cell viability, attachment, and osteogenic differentiation. These findings indicate that the 3D-printed scaffold with a PCL-to-LDH ratio of 2 : 1 is a promising platform for localized ALN delivery and bone tissue engineering applications.
Related
- Functionalization of polycaprolactone scaffolds for tissue engineering: molecular cues, bioactive cell–material interfaces, and translational perspectives
- From Seaweed to Science: Alginate Scaffolds in Shaping the Future of Tissue Engineering
- Three-dimensional PCL/collagen electrospun scaffolds with enlarged pores promote cell infiltration for vascular tissue engineering.
- Development of Hydrogel-Cellulose Nanofiber Hybrid Scaffolds for Potential Cutaneous Wound-Healing Applications
- Synthesis of Nitrogen‐Containing Heterocyclic Scaffolds and Applications in Scaffold Hopping: Development of an Aripiprazole Analog
BibTeX
@article{shirazian2026development,
title = {{Development of alendronate-loaded 3D-printed PCL/LDH scaffolds for controlled drug delivery in bone tissue engineering.}},
author = {Mohammad Amin Shirazian and Aryan Ekhlasi and Ghazal Belgheisi and Masoumeh Haghbin Nazarpak and Mehran Solati-Hashjin},
journal = {RSC advances},
year = {2026},
month = oct,
doi = {10.1039/d6ra07618a},
url = {https://europepmc.org/article/MED/42846630},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Development of alendronate-loaded 3D-printed PCL/LDH scaffolds for controlled drug delivery in bone tissue engineering.
AU - Mohammad Amin Shirazian
AU - Aryan Ekhlasi
AU - Ghazal Belgheisi
AU - Masoumeh Haghbin Nazarpak
AU - Mehran Solati-Hashjin
PY - 2026
DA - 2026/10/07
JO - RSC advances
DO - 10.1039/d6ra07618a
UR - https://europepmc.org/article/MED/42846630
AB - Bone tissue engineering has made significant advances in recent years; however, the development of scaffolds that not only support tissue regeneration but also effectively deliver therapeutic agents remains a major challenge. The present study investigates the fabrication and evaluation of 3D-printed polycaprolactone (PCL)/layered double hydroxide (LDH) hybrid scaffolds incorporating alendronate (ALN) for bone tissue engineering applications. First, LDH particles were synthesized via a co-precipitation method and loaded with ALN. Subsequently, scaffolds with varying PCL-to-LDH ratios (2 : 1, 3 : 1, 4 : 1, and 5 : 1) were fabricated and characterized. Field emission scanning electron microscopy (FE-SEM) revealed the characteristic hexagonal morphology of the LDH particles, while X-ray diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR) analyses confirmed the successful intercalation of ALN into the LDH structure. Among the different formulations, the scaffold with a PCL-to-LDH ratio of 2 : 1 exhibited the best overall performance. The incorporation of LDH into this scaffold improved hydrophilicity, reducing the water contact angle from ∼90° to 60°, increasing the ultimate tensile strength from ∼30 to 90 MPa, enhancing the elastic modulus from ∼350 to 750 MPa, and reducing the elongation at break from ∼170% to 50%. Furthermore, ALN was uniformly dispersed within the polymer matrix, resulting in a highly similar biphasic drug release profile consisting of a slight initial burst release during the first 7 days, followed by a sustained release phase extending up to 28 days. Biological evaluations, including MTT assays, cell adhesion studies, and alkaline phosphatase (ALP) activity measurements, further demonstrated that this scaffold promoted superior cell viability, attachment, and osteogenic differentiation. These findings indicate that the 3D-printed scaffold with a PCL-to-LDH ratio of 2 : 1 is a promising platform for localized ALN delivery and bone tissue engineering applications.
SN - 2046-2069
ER -